Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen

CRISPR Therapeutics

Medical stocks, in general, aren't enjoying the market-wide reversal we're seeing in the back half of 2023. The Morningstar US Healthcare Index, which measures a range of biotech, pharma, medical device and healthcare facility companies, has returned less than 1% since January.

3 ‘Strong Buy' Biotech Stocks You Should Be Loading Up On Now

Moderna (MRNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Moderna (MRNA) Ahead of Earnings?

Humana

Johnson & Johnson

Healthcare has been a laggard this year. A slowpoke, a dawdler, an idler.

3 Cheap Healthcare Stocks That Smart Investors Will Snap Up Now

Investors' focus will likely be on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates when it reports second-quarter earnings.

Moderna (MRNA) to Report Q2 Earnings: Will It Beat Estimates?

Novavax

Pfizer

Pfizer, Moderna and Novavax are slated to deliver new single-strain Covid shots targeting the omicron subvariant XBB.1.5 in September.

New Covid vaccines are coming to the U.S. this fall, but uptake may be low — Here's why

BioNTech SE

BioNTech and Moderna will likely always be compared due to the phenomenal success of their COVID vaccines. The two companies will report Q2 2023 earnings early next month - revenues may well disappoint the market. Both companies are pinning their hopes on the emergence of a private COVID market, however - which could be worth >$20bn per annum.

BioNTech And Moderna: Fallen Angels Of The COVID Era Are Buys Ahead Of Earnings

ARK Genomic Revolution Multi-Sector ETF

ARK Innovation ETF

Superstar investor Cathie Wood bought shares of Moderna over a period of two days this week. The biotech company may become a respiratory vaccine giant -- with coronavirus, RSV, and flu vaccines -- in just a few years.

Cathie Wood Is Buying Up Shares of This Beaten-Down Biotech. Should You?

Merck

Merck , along with its partner Moderna , began a late-stage study to evaluate their experimental mRNA-based cancer vaccine in combination with cancer therapy Keytruda, the companies said on Wednesday.

Merck, Moderna begin late-stage study of mRNA cancer vaccine

Merck & Co. MRK, -1.16% and Moderna Inc. MRNA, -0.93% said Wednesday they have launched a Phase 3 trial of Moderna's V940 in combination with Merck's Keytruda as a treatment for patients with high-risk, or Stage IIB-IV melanoma. The trial is the first Phase 3 study of a planned comprehensive clinical development program being initiated following positive data from a Phase 2 trial that was reported at two cancer conferences, AACR and ASCO, earlier this year.

Merck and Moderna launch late-stage trial of V940 with Keytruda as treatment for high-risk melanoma

RAHWAY, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the initiation of the pivotal Phase 3 randomized V940-001 clinical trial evaluating V940 (mRNA-4157), an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA, Merck's anti-PD-1 therapy, as an adjuvant treatment.

Merck and Moderna Initiate Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk (Stage IIB-IV) Melanoma

Intellia Therapeutics

Vertex Pharmaceuticals

Growth investors are frequently looking for biotech stocks to buy. So what exactly is a biotech stock?

The 3 Most Undervalued Biotech Stocks to Buy Now: July 2023

Netflix

Target

FOMO is carrying the day, week and month on Wall Street. And the rally is starting to spread beyond the tech sector.

Obey the Sell Signals: 3 Blue-Chip Stocks to Let Go

The market is ignoring Moderna due to its reliance on one product today. But that could be a mistake.

Prediction: This Beaten-Down Stock Will Be a Biotech Giant by 2030

Moderna is on track to achieve about $2B of its FY23 $5B COVID vaccine revenue target in the first half but may fall short unless sales momentum improves in H2. The company expects to commercialize its RSV vaccine, demonstrating the immense potential of its technology. Improved dip buying sentiments suggest that MRNA could have bottomed out.

Moderna: Buy While It's Cheap (Rating Upgrade)

Amyris

MannKind

Ocugen, Inc.

Cassava Sciences Inc

VBI Vaccines

Biotech may be a great sector for risk-seeking investors to find opportunity. That said, for every biotech stock worth buying, there are plenty that fit into the “biotech stocks to sell” category.

7 Biotech Stocks to Sell in July

CAMBRIDGE, MA / ACCESSWIRE / July 13, 2023 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 3, 2023 to report its second quarter 2023 financial results, and provide a corporate update.

Moderna to Report Second Quarter 2023 Financial Results on Thursday, August 3, 2023

Disney

Amazon Prime shopping days are here, and everyone loves good deals, Barron's looked for some in the stock market, and found 15 stocks primed to go higher.

Prime Day for Stocks? Disney, Moderna and 13 More That Look Like Bargains.

APA Corporation

Bio-Rad Laboratories

Caesars Entertainment

Enphase Energy

Etsy

Halliburton

SolarEdge Technologies

Warner Bros Discovery Inc

Analysts have the typical hopes for the S&P 500 in the next 12 months. But they're especially bullish on a small handful of stocks.

10 Stocks Will Make You 30% Richer Than Others In A Year, Analysts

Archer-Daniels-Midland Company

Apogee Enterprises

Cavco Industries

Foot Locker

Heritage-Crystal Clean

Heartland Express

Oxford Industries

Patterson-UTI Energy

State Street

The phrase “Perfect 10” doesn't just apply to bathing beauties. It's the name of one of my favorite hypothetical stock portfolios.

The Perfect 10 Portfolio Is Ready to Roll

The Fed has forecast a recession -- but some economists aren't so sure it will happen. It's important to take a long-term view when investing and consider your own investing style.

Are We Heading for a Recession? Here's What Investors Should Do.

Moderna, Inc. has submitted multiple regulatory submission of mRNA-1345 as an RSV vaccine in older adults ages 60 and older; additional regulatory submissions expected in coming months. The global respiratory syncytial virus market is expected to reach $4.20 billion by 2027. GlaxoSmithKline obtained regulatory approval of its RSV vaccine in adults ages 60 and older known as Arexvy; analysts estimate that it could generate peak sales of $2.5billion.

Moderna: Potential To Get Second Product To Market

Shares of pharmaceutical concern Moderna Inc (NASDAQ:MRNA) are 4.3% lower today at $118.25, one day after the company inked a deal to research, develop, and manufacture mRNA medicines in China.

Wait Before Buying Moderna Stock, Says Bear Signal

Alongside the FDA filing, Moderna (MRNA) submits similar filings in Europe and Australia, seeking approval for using its RSV vaccine in older adults aged 60 years and above.

Moderna (MRNA) Initiates Rolling BLA Filing for RSV Vaccine

All three companies are working on updated vaccines for COVID. A new variant, XBB.1.5, led to a spike in COVID cases in China earlier this year.

A Big Test Is Looming for Pfizer, Moderna, and Novavax

The defensive stocks sector has been underperforming most - if not all - of the remaining cyclical sectors in the U.S. economy. These preferences come from underlying dynamics in the money markets and where investors think we are in the business cycle.

News for Moderna Stock (MRNA)